Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of solid-organ transplantation (SOT) and bone marrow transplantation, and are associated with high mortality. PTLDs represent a heterogeneous group of lymphoproliferative diseases, which show a spectrum of clinical, morphologic, and molecular genetic features ranging from reactive polyclonal lesions to frank lymphomas. We describe clinicopathologic features of 17 cases of PTLD after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which were analyzed by in situ hybridization for EBV and a panel of antibodies directed against numerous antigens, including CD20, PAX5, CD3, bcl-6, CD10, MUM-1/IRF4, CD138, Kappa, Lambda, CD30, CD15, and Ki67. The cases included 13 males and 4 females with a median age of 31 years (range 9–49 years) and the PTLDs developed 1.5–19 months post-transplant (mean 4.7 months). The histological types indicated five cases of early lesions, two of plasmacytic hyperplasia and three of infectious mononucleosis-like PTLD. Eight cases were polymorphic PTLD, and four were monomorphic PTLD, including three of diffuse large B cell lymphoma, and one of plasmablastic lymphoma. Foci and sheets of necrosis were observed in five cases. The infected ratio of EBV was 88.2 %. Some cases were treated by reduction of immunosuppression, antiviral therapy, donor lymphocyte infusion, or anti-CD20 monoclonal rituximab. Eight cases died. The first half year after allo-HSCT is very important for the development of PTLD. The diagnosis of PTLD relies on morphology and immunohistochemistry, and EBV plays an important role in the pathogenesis of PTLD. The prognosis of PTLD is poor, and, notably, PTLD after allo-HSCT exhibits some features different from those of PTLD after SOT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet. 1984;1:583–7.

    Article  PubMed  CAS  Google Scholar 

  2. Swerdlow SH, Webber SA, Chadburn A, et al. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 343–9.

    Google Scholar 

  3. Zhang YN, Zhou XG, Wang CZ, et al. Clinicopathologic study of post-transplant lymphoproliferative disorders. Chin J Pathol. 2006;35(4):209–11.

    Google Scholar 

  4. Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, et al. Post-transplant lymphoproliferative disorders in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant. 2010;25:2089–98.

    Article  PubMed  Google Scholar 

  5. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2003;4:222–30.

    Article  Google Scholar 

  6. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342:1514–6.

    Article  PubMed  CAS  Google Scholar 

  7. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16.

    PubMed  CAS  Google Scholar 

  8. Hoegh-Petersen M, Goodyear D, Geddes MN, et al. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplant. 2011;46:1104–12.

    Article  PubMed  CAS  Google Scholar 

  9. Kamani N, Kumar S, Hassebroek A, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2011;17:1783–9.

    Article  PubMed  Google Scholar 

  10. Xu LP, Huang XJ, Liu DH, et al. A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. Chin J Intern Med. 2007;46(12):996–9.

    Google Scholar 

  11. Xu LP, Liu DH, Liu KY, et al. The efficacy and safety of donor lymphocyte infusion to treat Epstein–Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation. Chin J Intern Med. 2010;49(11):955–8.

    Google Scholar 

  12. Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein–Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders. A histogenetic study. Am J Surg Pathol. 2006;30(12):1604–12.

    Article  PubMed  Google Scholar 

  13. Tsao L, His ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007;131:1209–18.

    PubMed  Google Scholar 

  14. Ibrahim HAH, Naresh KN. Posttransplant lymphoproliferative disorders. Adv Hematol. 2012;2012:1–11.

    Article  Google Scholar 

  15. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85(2):552–65.

    PubMed  CAS  Google Scholar 

  16. Wu TT, Swerdlow SH, Locker J, et al. Recurrent Epstein–Barr virus-associated lesions in organ transplant recipients. Hum Pathol. 1996;27(2):157–64.

    Article  PubMed  CAS  Google Scholar 

  17. Borenstein J, Pezzella F, Gatter KC. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology. 2007;51:774–7.

    Article  PubMed  CAS  Google Scholar 

  18. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferative, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011;96(7):1067–71.

    Article  PubMed  Google Scholar 

  19. Harris NL, Swerdlow SH, Frizzera GF, et al. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, et al., editors. WHO classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 264–9.

    Google Scholar 

  20. Gibson SE, Swerdlow SH, Craig FE, et al. EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorders? Am J Surg Pathol. 2011;35(6):807–15.

    Article  PubMed  Google Scholar 

  21. Opelz G, Dohler B. Impact of HLA mismatching on incidence of posttransplant at non-Hodgkin lymphoma after kidney transplantation. Transplantation. 2010;89:567–72.

    Article  PubMed  CAS  Google Scholar 

  22. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

    Article  PubMed  CAS  Google Scholar 

  23. Kamiura T, Miyamoto T, Kawano N, et al. Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95(6):725–30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Peking University People’s Hospital, Beijing, 100044, People’s Republic of China

    Ding-Bao Chen, Qiu-Jing Song, Yun-Xin Chen & Dan-Hua Shen

  2. Institute of Hematology, Peking University People’s Hospital, Beijing, People’s Republic of China

    Yu-Hong Chen

Authors
  1. Ding-Bao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiu-Jing Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun-Xin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu-Hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dan-Hua Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ding-Bao Chen.

About this article

Cite this article

Chen, DB., Song, QJ., Chen, YX. et al. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97, 117–124 (2013). https://doi.org/10.1007/s12185-012-1244-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1244-1

Keywords

Search

Navigation